THERAPEUTICSMD INC (TXMD)

US88338N2062 - Common Stock

1.885  +0.01 (+0.27%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
2.57M
-96.04%		69.96M
2,622.18%		1.302M
-98.14%		9.18M
605.07%
EBITDA
YoY % growth
-78.84M
48.97%		11.85M
115.03%		-7.601M
-164.14%		N/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
-79.58M
48.84%		10.66M
113.40%		-8.523M
-179.95%		4.794M
156.25%
Operating Margin
-3,096.50%15.24%-654.61%52.22%
EPS
YoY % growth
-21.50
35.82%		11.80
154.88%		N/A0.36

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2023
Q2Q % growth		 -0.13
95.85%		-0.05-0.08-154.90%
Q2 2023
Q2Q % growth		 -0.24
-101.94%		-0.07-0.17-236.13%
Q1 2023
Q2Q % growth		 -0.37
93.50%		0.06-0.43-704.58%
Q4 2022
Q2Q % growth		 8.23
264.60%		-1.139.36826.90%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 502K
-56.35%		612K-110K-17.97%
Q3 2023
Q2Q % growth		 -50K
-114.29%		510K-560K-109.80%
Q2 2023
Q2Q % growth		 440K
25.71%		510K-70K-13.73%
Q1 2023
Q2Q % growth		 420K
-40.00%		1.734M-1.314M-75.78%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPSN/A N/A 0% 0%
RevenueN/A N/A 0% 0%